Back to top
more

Alkermes (ALKS)

(Real Time Quote from BATS)

$29.15 USD

29.15
263,087

-0.08 (-0.27%)

Updated Nov 13, 2024 01:26 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

4-Sell of 5       4  

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth F Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 26% (65 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Intercept (ICPT) Earnings Miss, Sales Top Estimates in Q2 (Revised)

by Zacks Equity Research

Intercept (ICPT) posts a wider Q2 loss while sales beat estimates. The company reissues guidance.

Eli Lilly (LLY) Misses on Q1 Earnings, Lowers Earnings Guidance

by Zacks Equity Research

Eli Lilly's (LLY) earnings and sales miss second-quarter estimates. The company lowers its earnings outlook for 2022. The stock falls in pre-market trading.

PacBio's (PACB) Q2 Earnings Match Estimates, Revenues Lag

by Zacks Equity Research

PacBio (PACB) sees strength in Q2 segmental revenues, led by robust consumable and instrument sales.

BD (BDX) Beats on Q3 Earnings and Revenues, Raises FY22 View

by Zacks Equity Research

The majority of BD's (BDX) core units witness strong revenue growth in the fiscal third quarter.

Abiomed (ABMD) Q1 Earnings Top Estimates, Margins Down

by Zacks Equity Research

Abiomed's (ABMD) strength in Impella product revenues drives its Q1 top line.

FATE's Q2 Loss Narrower Than Expected, Pipeline in Focus

by Zacks Equity Research

FATE reports a narrower loss and higher collaboration revenues in the second quarter.

Glaukos (GKOS) Q2 Earnings Miss Estimates, Revenues Beat

by Zacks Equity Research

Glaukos' (GKOS) Q2 revenues fall year over year but beat estimates. Lower revenues along with higher expenses hurt margins significantly.

McKesson's (MCK) Q1 Earnings and Revenues Beat Estimates

by Zacks Equity Research

McKesson's (MCK) fiscal first-quarter 2023 results benefit from segmental growth.

Inari Medical (NARI) Q2 Earnings Beat, CEO Transition in 2023

by Zacks Equity Research

Inari Medical's (NARI) second-quarter results benefit from significant progress made across all its growth drivers.

Intercept (ICPT) Earnings and Sales Miss Estimates in Q2

by Zacks Equity Research

Intercept (ICPT) posts a wider Q2 loss and sales miss estimates. The company reissues guidance.

AmerisourceBergen (ABC) Q3 Earnings & Revenues Top Estimates

by Zacks Equity Research

AmerisourceBergen's (ABC) fiscal third-quarter results benefit from segmental growth.

Gilead (GILD) Q2 Earnings & Sales Top, Revenue Outlook Upped

by Zacks Equity Research

Gilead (GILD) reports better-than-expected second quarter results on strong HIV business. The company also raises its annual revenue guidance.

DaVita (DVA) Beats on Q2 Earnings, Reiterates FY22 EPS View

by Zacks Equity Research

DaVita (DVA) records an overall solid Q2 performance owing to strength in its Other segment's revenues and uptick in total U.S. dialysis treatments.

Zimmer Biomet (ZBH) Q2 Earnings Top Estimates, 2022 View Up

by Zacks Equity Research

The contraction in Zimmer Biomet's (ZBH) gross margin is concerning.

Fresenius Medical's (FMS) Q2 Earnings Miss, Revenues Top

by Zacks Equity Research

Fresenius Medical's (FMS) second-quarter earnings benefit from strong performance across all the geographic regions and segments. However, rising costs hurt margins.

IDEXX (IDXX) Q2 Earnings Surpass Estimates, 2022 View Down

by Zacks Equity Research

IDEXX's (IDXX) Q2 top-line benefits from strong sales at the CAG and Water businesses.

Avantor's (AVTR) Stock Falls 8.8% Since Q2 Earnings Miss

by Zacks Equity Research

Avantor's (AVTR) robust performance across majority of its segments drives its Q2 sales, despite business challenges.

PerkinElmer (PKI) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results benefit from a solid performance at Discover & Analytics Solutions business.

Teleflex's (TFX) Q2 Earnings Top Estimates, 2022 View Down

by Zacks Equity Research

For UroLift, Teleflex (TFX) witnesses revenue declines in all sites of service, including hospital, ASC and physician's office.

    Alkermes (ALKS) Loses 16.2% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

    by Zacks Equity Research

    Alkermes (ALKS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

    Zacks Earnings ESP: A Better Way to Find Earnings Surprises for Medical

    by Zacks Equity Research

    Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.

    Chemed (CHE) Q2 Earnings Surpass Estimates, Margins Grow

    by Zacks Equity Research

    Chemed (CHE) reports better-than-expected earnings in the second quarter, with a robust performance by the Roto-Rooter segment driving the top line.

    Edwards Lifesciences (EW) Q2 Earnings Meet Estimates, Margins Up

    by Zacks Equity Research

    Edwards Lifesciences (EW) posts Q2 earnings in line with the Zacks Consensus Estimate, with robust performances across all product groups driving the top line.

    DexCom (DXCM) Q2 Earnings Match Estimates, Revenues Miss

    by Zacks Equity Research

    Despite the top line missing estimates, DexCom's (DXCM) second-quarter results reflected strong domestic and international revenue growth.

    Integer Holdings (ITGR) Q2 Earnings Miss, FY22 View Revised

    by Zacks Equity Research

    Integer Holdings' (ITGR) second-quarter results reflect robust Medical Sales besides strength in the majority of product lines.